Amprologix Celebrates Research Excellence at the University of…
7 November 2025Amprologix celebrates research excellence at the University of Plymouth as CSO Professor Mat Upton presents the Research Excellence Award to…
Amprologix celebrates research excellence at the University of Plymouth as CSO Professor Mat Upton presents the Research Excellence Award to…
Amprologix has raised £740,000 to accelerate the development of our breakthrough antibiotic Epidermicin NI01. This investment also supports our AI-driven…
We are pleased to announce that Professor Mat Upton, Chief Scientific Officer at Amprologix, will represent the company at the…
This summer we’ve been pleased to welcome Rutendo Mupfumi from the University of Plymouth to the Amprologix lab. As part…
Amprologix joins a global network of innovators We're proud to announce that Amprologix is one of the 103 finalists selected…
Amprologix has raised £740,000 to accelerate the development of our breakthrough antibiotic Epidermicin NI01. This investment also supports our AI-driven antimicrobial discovery platform, reinforcing our mission to tackle global antimicrobial resistance by developing novel antimicrobials.
Innovate UK has awarded Amprologix £1M of Biomedical Catalyst funding to continue the Tobraderm project 1st March 2024 Amprologix is delighted to receive confirmation of its success in securing a £1M Biomedical Catalyst award from Innovate UK for its Tobraderm project. The project will advance the company’s NI01 lead compound through late-preclinical testing for common […]
